{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:11:12Z","timestamp":1778944272757,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102557","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:12:46Z","timestamp":1775059966000},"page":"102557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association Between Proto-Oncogene N-RAS Transcript Level and Overall Survival in Node-Negative Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6998-302X","authenticated-orcid":false,"given":"Donghyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6671-7002","authenticated-orcid":false,"given":"Yasser","family":"Ged","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8548-6948","authenticated-orcid":false,"given":"Parminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilal","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-2626","authenticated-orcid":false,"given":"Yousef","family":"Zakharia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102557_bib0001","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-pathol-012513-104703","article-title":"Origins of bladder cancer","volume":"11","author":"Czerniak","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.clgc.2026.102557_bib0002","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab Vedotin and Pembrolizumab in bladder cancer","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102557_bib0003","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA630","article-title":"Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study","volume":"44","author":"Galsky","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102557_bib0004","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/cncr.23848","article-title":"A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience","volume":"113","author":"Dash","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2026.102557_bib0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102557_bib0006","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102557_bib0007","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"25","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102557_bib0008","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1111\/bju.12274","article-title":"Eligibility for neoadjuvant\/adjuvant cisplatin-based chemotherapy among radical cystectomy patients","volume":"113","author":"Thompson","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2026.102557_bib0009","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines(R) insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2026.102557_bib0010","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102557_bib0011","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1007\/s00432-021-03582-x","article-title":"Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC","volume":"147","author":"Lee","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102557_bib0012","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2026.102557_bib0013","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clgc.2026.102557_bib0014","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.clgc.2026.102557_bib0015","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102557_bib0016","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2026.102557_bib0017","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2026.102557_bib0018","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1073\/pnas.87.22.9047","article-title":"Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma","volume":"87","author":"Theodorescu","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clgc.2026.102557_bib0019","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.juro.2009.01.011","article-title":"Activation of RAS family genes in urothelial carcinoma","volume":"181","author":"Boulalas","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102557_bib0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0304-3835(96)04372-8","article-title":"Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors","volume":"107","author":"Vageli","year":"1996","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clgc.2026.102557_bib0021","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2026.102557_bib0022","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.clgc.2026.102557_bib0023","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","article-title":"Gender and bladder Cancer: a Collaborative Review of etiology, Biology, and outcomes","volume":"69","author":"Dobruch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102557_bib0024","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2026.102557_bib0025","first-page":"495","article-title":"Copper transporter-CTR1 expression and pathological outcomes in platinum-treated muscle-invasive bladder cancer patients","volume":"36","author":"Kilari","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2026.102557_bib0026","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1134\/S0006297917040095","article-title":"MicroRNA-294 promotes cellular proliferation and motility through the PI3K\/AKT and JAK\/STAT pathways by upregulation of NRAS in bladder cancer","volume":"82","author":"Li","year":"2017","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.clgc.2026.102557_bib0027","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102557_bib0028","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-018-0489-5","article-title":"Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors","volume":"7","author":"Conroy","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2026.102557_bib0029","unstructured":"Testing the role of DNA released from tumor cells into the blood in guiding the use of immunotherapy after surgical removal of the bladder for bladder cancer treatment, MODERN Study. Accessed: February 23, 2026. <https:\/\/clinicaltrials.gov\/study\/NCT05987241>."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:29:18Z","timestamp":1778941758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1558767326000571"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102557","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Proto-Oncogene N-RAS Transcript Level and Overall Survival in Node-Negative Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102557","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102557"}}